Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma arising from the ovary. It is characterized by the presence of malignant epithelial cells with clear cytoplasm in a fibrotic stroma.
Biomarker and diagnostic research for ovarian clear cell malignant adenofibroma has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 2 PHASE3. Research is primarily sponsored by academic and government institutions.
6 publications have been identified in PubMed for ovarian clear cell malignant adenofibroma. Research spans Case Report / Case Series (33%), Diagnostic / Biomarker (17%), and Review / Meta-Analysis (17%).
Ordoñez Arrillaga A (2026). [PMID: 41579581](https://pubmed.ncbi.nlm.nih.gov/41579581/). *Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia*. [Case Report / Case Series]
Barbu LA (2025). [PMID: 40384190](https://pubmed.ncbi.nlm.nih.gov/40384190/). *Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie*. [Review / Meta-Analysis]
Lin LH (2025). [PMID: 39869066](https://pubmed.ncbi.nlm.nih.gov/39869066/). *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists*. [Epidemiology / Natural History]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
Parisi X (2024). [PMID: 37715657](https://pubmed.ncbi.nlm.nih.gov/37715657/). *International journal of surgical pathology*. [Diagnostic / Biomarker]
Diab RA (2024). [PMID: 38975375](https://pubmed.ncbi.nlm.nih.gov/38975375/). *Cureus*. [Case Report / Case Series]
Takeuchi M (2024). [PMID: 38658503](https://pubmed.ncbi.nlm.nih.gov/38658503/). *Japanese journal of radiology*. [Basic Science / Preclinical]
AI-curated news mentioning ovarian clear cell malignant adenofibroma
Updated Jul 19, 2026
A case report highlights a durable response to the combination of pembrolizumab and axitinib in a patient with platinum-resistant ovarian clear cell carcinoma. This finding may inform future treatment strategies for this challenging cancer subtype.
Research highlights the role of RBM4 as a pro-oncogenic factor in the progression of ovarian clear cell carcinoma. This discovery could inform future therapeutic strategies targeting this specific cancer type.